Clinically, elevated SIRT1 expression in NSCLC correlates with a poor response to immunotherapy and shortened patient survival, underscoring its role as a redox-driven regulator of tumor maintenance [105]. This evidence concerns the gene SIRT1 and non-small cell lung carcinoma.